Vnitr Lek 2006, 52(5):459-464

Healing of skin lesions in diabetic foot syndrome during hospitalization

A. Jirkovská
Centrum diabetologie IKEM, Praha, přednostka prof. MUDr. Terezie Pelikánová, DrSc.

Wound healing during the diabetic foot disease is indicated to in-patient treatment in case of non-healing wound, in case of serious infection and/or critical ischemia and in case of necessity of surgical treatment. Diabetic foot disease is the main reason for in-patient treatment of people with diabetes, which our experience confirms. Chronic wound is characterised by non-healing for at least 4 weeks. Ischemia and recurrent trauma caused by incomplete off-loading, prolong inflammation and infection are the main reasons for difficult healing of chronic wound. Infection is also leading cause for prolonged hospitalisation of patients with diabetic foot disease. Local decrease of grow factors and increase of tissue protease are characteristics of chronic wound. The process of wound healing is characterized by a cascade of interrelated events involving infection and inflammatory factors. The results of these investigations led to the moist wound healing concept and use of growth factors and bioengineered skin substitutes. We have good experience with the use of xenotransplant skin substitues in the treatment of diabetic foot. Off loading techniques including total contact casting, local therapy by debridement and skin substitutes had the best evidence based efficacy. We are introducing new method of the treatment of diabetic foot - VAC - vacuum assisted closure. The fundamental principle in the therapy during in-patient period, is comprehensive approach; the omitting of any of the principle of the therapy - e.g. the off-loading of the ulcers, the infection and ischemia control, may contribute to its failure.

Keywords: diabetic foot disease; chronic wound treatment; foot infection

Received: June 3, 2005; Accepted: June 3, 2005; Published: May 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Jirkovská A. Healing of skin lesions in diabetic foot syndrome during hospitalization. Vnitr Lek. 2006;52(5):459-464.
Download citation

References

  1. Eneroth M, Larsson J, Apelqvist J. Deep foot infections in patients with diabetes and foot ulcer: an entity with different characteristics, treatments, and prognosis. J Diab Comp 1999; 13: 254-263. Go to original source... Go to PubMed...
  2. Caputo G, Cavanagh PR, Ulbrecht JS et al. Assessment and management of foot disease in patients with diabetes. N Engl J Med 1994; 331: 854-860. Go to original source... Go to PubMed...
  3. Caputo GM. The rationale use of antimicrobial agents in diabetic foot infection.. In: Boulton AJM, Connor H, Cavanagh PR (eds). The foot in diabetes. Chichester: John Wiley and sons, LTD 2000: 143-151. Go to original source...
  4. Mason J, Keeffet CO, Hutchinson A et al. A systematic review of foot ulcer in patients with type 2 diabetes mellitus. II: Treatment. Diabet Med 1999; 16: 889-909. Go to original source... Go to PubMed...
  5. Chantelau E, Tanudjaja T, Altenhofer F et al. Antibiotic treatment for uncomplicated forefoot ulcers in diabetes: a controlled trial. Diabet Med 1996; 13: 156-159. Go to original source... Go to PubMed...
  6. Jeffcoat WJ, Price P, Harding KG. Wound healing and treatments for people with diabetic foot ulcers. Diabetes Metab Res Rev 2004; 20(Suppl 1): S78-S89. Go to original source... Go to PubMed...
  7. Steed DL. Role of growth factors in the treatment of diabetic foot ulceration. In: Veves A, Giurini JM, LoGerfo FW (eds). The diabetic foot. Totowa: Human Press 2002: 385-395. Go to original source...
  8. Katz MH, Alvarez AF, Kirsner RS et al. Human wound fluid from acute wounds stimulates fibroblasts and endotelial cell growth. J Am Acad dermatol 1991; 25: 1054-1058. Go to original source... Go to PubMed...
  9. Bucalo B, Eaglstein WH, Falanga V. Inhibition of cell proliferation by chronic wound fluid. Wound Rep Regen 1993; 1: 181-186. Go to original source... Go to PubMed...
  10. Grey JE, Jones V, Harding KG. Principles of treatment of chronic wound. In: Veves A, Giurini JM, LoGerfo FW (eds). The diabetic foot. Totowa: Human Press 2002: 247-278. Go to original source...
  11. Eldor R, Raz I, Ben Yehudat A et al. New and experimental approaches to treatment of diabetic foot ulcers: a comprehensive review of emerging treatment strategies. Diabet Med 2004; 21: 1161-1173. Go to original source... Go to PubMed...
  12. Courtney M. The use of larval therapy in wound management in the UK. J Wound Care 1999; 8: 177-179. Go to original source... Go to PubMed...
  13. Armstrong DG, Salas P, Short B et al. Maggot therapy in "lower-extremity hospice" wound care: fewer amputations and more antibiotic-free days. J Am Podiatr Med Assoc 2005; 95: 254-257. Go to original source... Go to PubMed...
  14. Kalani M, Brismar K, Fagrell B et al. Transcutaneous oxygen tension and toe blood pressure as predictors for outcome of diabetic foot ulcers. Diabetes Care 1999; 22: 147-151. Go to original source... Go to PubMed...
  15. Fife CE, Buyukcakir C, Otto GH et al. The predictive value of transcutaneous oxygen tension measurement in diabetic lower extremity ulcers treated with hyperbaric oxygen therapy: a retrospecitve analysis of 1 144 patients. Wound Repair Regen 2002; 10: 198-207. Go to original source... Go to PubMed...
  16. Falanga V, Oian SV, Danielpour D et al. Hypoxia upregulates synthesis of TGF β 1 by human fibroblasts. J Invest Dermatol 1991; 97: 634-637. Go to original source... Go to PubMed...
  17. Jirkovská A. Aktuální problematika syndromu diabetické nohy. In: Perušičová J (ed). Trendy soudobé diabetologie. Praha: Galén 2001: 51-87.
  18. Piaggesi A, Viacava P, Rizzo L et al. Semiquantitative analysis of the histopathological features of the neuropathic foot ulcers. Diabetes Care 2003; 26: 3123-3128. Go to original source... Go to PubMed...
  19. Steed DL. Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic ulcers. The diabetic ulcer study group. J Vasc Surg 1995; 21: 71-78. Go to original source... Go to PubMed...
  20. Smiell JM, Wieman TJ, Steed DL et al. Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor BB) in patients with non-healing, lower extremity diabetic ulcers: a combined analysis of four randomized studies. Wound Repair Regen 1999; 7: 335-346. Go to original source... Go to PubMed...
  21. Veves A, Sheehan P, Pham HT. A randomized, controlled trial of Promogran (a collagen/oxidized regenerated cellulose dressing) vs standard treatment in the management of diabetic foot ulcers. Arch Surg 2002; 137: 822-827. Go to original source... Go to PubMed...
  22. Badiavas EV, Falanga V. Treatment of chronic wounds with bone-marrow derived cells. Arch Dermatol 2003; 139: 510-516. Go to original source... Go to PubMed...
  23. Falanga V, Isaacs C, Paquette D et al. Wounding of bioengineered skin: cellular and molecular aspects after injury. J Invest Dermatol 2002; 119: 653-660. Go to original source... Go to PubMed...
  24. Armstrong DG, Lavery LA, Abu-Rumman P et al. Outcomes of subathmospheric pressure dressing therapy on wounds of the diabetic foot. Ostotomy Wound Management 2002; 48: 64-68.
  25. Armstrong DG, Boulton AJM, Banwell PE. Topical negative pressure: management of complex diabetic foot wounds. Oxford: The Oxford Wound Healing Society 2004.




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.